← Back to all signals
RESEARCH PAPER ANALYSIS

Lifetime prevalence of cancer in Germany between 2010 and 2019: An analysis based on aggregated data.

AI interpretation is pending for this paper.

Open original publication →
PMID41183044
JournalPloS one
Publication Date2025-11-03
Ingested2026-08-02 12:03 AM
EXECUTIVE SUMMARY

What the AI sees

Not AI summarized yet.

WHY IT MATTERS

Research significance

Pending deeper interpretation.

ABSTRACT

Source abstract

BACKGROUND: Many cancer survivors (i.e., individuals alive who have been diagnosed with cancer at some point in their lives) remain under surveillance by doctors and medical professionals regardless of the outcome of their treatment as they face the risk of recurrence and/or encounter symptoms and other health-related issues. With advancements in cancer early detection, diagnostics, and treatment strategies, along with an increasingly older population, the number of cancer survivors is steadily increasing. Since information on epidemiological indicators of cancer survivors is limited in Germany, the present study aims to estimate its prevalence between 2010 and 2019. METHODS: The annual age- and sex-specific lifetime prevalence of cancer was estimated using a partial differential equation. The calculation was based on comprehensive data obtained from the Centre for Cancer Registry Data (Zentrum für Krebsregisterdaten, ZfKD), the Central Research Institute of Ambulatory Health Care in Germany (Zentralinstitut für die kassenärztliche Versorgung, Zi), and the German Federal Statistical Office. RESULTS: Our estimates indicate a rise in lifetime prevalence of cancer between 2010 and 2019 across all ages up to 85, particularly pronounced among older individuals. By 2019, the highest prevalence was estimated to be 49% of males and 28% of females at age 85. In contrast, childhood cancer was relatively rare, affecting less than 0.3% of girls and boys until the age of 18. Generally, the prevalence of cancer was higher among males than females. Overall, the number of cancer survivors aged up to 85 was estimated to increase from 2.51 million in 2010 to over 5.07 million in 2019. CONCLUSIONS: The findings indicate a substantial rise in the lifetime prevalence of cancer in 2019 compared to 2010. Considering a cancer patient as cured based on a specific timeframe may lead to an underestimation of the future demand for healthcare resources.

SUPPORTING PAPER SET

32 more papers to review

Ranked by current scoring engine
1 Late cardiopulmonary morbidity in patients with Hodgkin lymphoma: a retrospective nationwide registry study. Annals of hematology 66.6 2 Endoscopic techniques for removal of intraorbital foreign bodies - a clinical series. Acta neurochirurgica 60.9 3 Existing 'In-Between': A Qualitative Exploration of Individual, Interpersonal and Structural Influences on Empowerment Among Young Adults With Chronic Health Conditions. Health expectations : an international journal of public participation in health care and health policy 57.5 4 Transcriptome Analysis Identifies a Myeloid-Like Signature in Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia Patients With Poor Response to CD19 Chimeric Antigen Receptor T Cell Therapy. Cancer medicine 83.78 5 Combined ATR and mitotic inhibition is effective against MYCN-amplified neuroblastoma. Molecular cancer therapeutics 59.9 6 Computational identification of phytochemical NMDAR pore-targeting candidates for radiation-induced cognitive decline. In silico pharmacology 63.2 7 Examining the roles of socioeconomic status and relevant health correlates (body mass index, diet quality, and inflammation) for neuropsychological function in young adults. Acta neuropsychiatrica 65.0 8 Unexpected Adverse Events During Anti-GD2 Immunotherapy Following T- and B-Cell Depleted Haploidentical Transplantation in High-Risk Neuroblastoma: A Pediatric Case Report. Pediatric blood & cancer 47.64 9 Feeding, Fear, and Acceptance: Caregivers' Experiences of Nutritional Support During Childhood Cancer Treatment. Pediatric blood & cancer 59.24 10 Cardio-protection and monitoring for early phase clinical trials: Recommendations from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortium. Journal of the National Cancer Institute 82.34 11 Beyond Molecular Diagnosis: Integrating Therapeutic Drug Monitoring and Pharmacogenetics for Precision Use of Tyrosine Kinase Inhibitors in Pediatric Hematological Malignancies. Therapeutic drug monitoring 55.06 12 Re: Erbas IM: Reconsidering the Interpretation of Thyroid Cancer Risk in Pediatric Hashimoto Thyroiditis. Hormone research in paediatrics 47.5 13 Hepatocellular carcinoma screening in a tertiary hospital. What are we missing? Oncology 68.2 14 Infection in Pediatric Auditory Brainstem Implant: A Case Study and Scoping Review. Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology 51.9 15 Mechanisms of Progression of Myeloid Preleukemia to Transformed Myeloid Leukemia in Children with Down Syndrome. Cancer cell 48.85 16 Why Complete Pediatric Cancer Registration in Germany Requires Cross-Sector Reporting Obligations: A Registry Comparison Study. Klinische Padiatrie 57.5 17 Nail disorders in pediatric patients: Part 2. Clinical overview, diagnosis and management of inflammatory, pigmentary, and neoplastic etiologies. Journal of the American Academy of Dermatology 54.0 18 The Maternal-Placental-Fetal Liver Axis: A Mechanistic Framework for Understanding Benzene Developmental Hematotoxicity. Reproductive toxicology (Elmsford, N.Y.) 39.62 19 A Pediatric Case of Malignant Melanoma Successfully Treated With Adjuvant Nivolumab. The Journal of dermatology 47.5 20 Management of seizures in patients with brain tumors. Current opinion in neurology 76.7 21 Paraneoplastic Autoimmune Multiorgan Syndrome: Diagnostic Lessons for Pediatricians. Pediatrics 62.0 22 Intraparotid lipoma in a 15-year-old girl: MRI-based diagnosis of a rare parotid lesion. Radiology case reports 56.0 23 Pathways from chronic stress to cognitive decline: A multi-cohort mediation analysis of inflammation and immune-related gene expression. Brain, behavior, & immunity - health 49.1 24 High-Resolution Ultrasound in the Evaluation of Median and Superficial Radial Nerve Involvement in Neurofibromatosis Type 1. Ultrasound quarterly 54.0 25 Pacak-Zhuang syndrome with EPAS1 p.Pro531Leu somatic variant: one case report and literature review. Hematology (Amsterdam, Netherlands) 50.9 26 Beyond the Bones: Primary Prostatic Synovial Sarcoma in a Young Adult. Cureus 65.2 27 Multiple Extensive Odontogenic Keratocysts in a Child With Gorlin-Goltz Syndrome: A Case Report. Cureus 51.4 28 Behavior Change Interventions to Promote Healthy Lifestyles Among Adolescent and Young Adult Childhood Cancer Survivors: A Scoping Review. Cancer reports (Hoboken, N.J.) 61.2 29 [Survey on serum tetanus antibody levels in children with hematological malignancies post-chemotherapy in Zhejiang Province from 2022 to 2023]. Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine] 72.6 30 Utility of thyroid nodule to thyroid lobe volume ratio to measure fine needle aspiration cytologic malignancy risk of thyroid nodules in the pediatric population. International journal of pediatric otorhinolaryngology 68.5 31 Implementation of a universal psychosocial screening program across the pediatric cancer treatment trajectory: a standard of care. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 62.74 32 Conjunctival involvement with corneal extension in pediatric mycosis fungoides. Surgical and immunomodulatory management. Archivos de la Sociedad Espanola de Oftalmologia 60.0
PATIENT-FRIENDLY SUMMARY

Lifetime prevalence of cancer in Germany between 2010 and 2019: An analysis based on aggregated data.

For education only—not personal medical advice.

Before you continue

AI-assisted research information

Neurocompute uses AI to summarize scientific papers, interpret research signals, and suggest relevant reference links. AI-generated content can be incomplete, misleading, or wrong, and generated links may be irrelevant or unavailable.

Our reviewed outputs have performed strongly to date, but past accuracy is not a guarantee. Verify summaries, scores, claims, and links against the original publication before relying on them.

This platform is for research and education only. It does not provide medical advice, diagnosis, treatment recommendations, or clinical guidance.

Pediatric cancer research intelligence graphic
PEDIATRIC CANCER VISUAL SYSTEM

Open the Research Intelligence Map

Explore the active pediatric oncology analysis view.

Expand Intelligence View →
Full Pediatric cancer research intelligence graphic